Literature DB >> 17209527

Drug evaluation: tesetaxel--an oral semisynthetic taxane derivative.

Maria Roche1, Helena Kyriakou, Michael Seiden.   

Abstract

Daiichi Sankyo Co Ltd (formerly Daiichi Seiyaku Co Ltd) was developing the oral semisynthetic taxane derivative tesetaxel for the potential treatment of cancer, including colorectal and gastric cancer. However, despite early signs of promise, in November 2006 tesetaxel was removed from Daiichi's development pipeline for failure to show clear benefit over existing, currently marketed agents for cancer chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17209527

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  5 in total

Review 1.  Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Authors:  E S Antonarakis; A J Armstrong
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-05-17       Impact factor: 5.554

Review 2.  Taxane anticancer agents: a patent perspective.

Authors:  Iwao Ojima; Brendan Lichtenthal; Siyeon Lee; Changwei Wang; Xin Wang
Journal:  Expert Opin Ther Pat       Date:  2015-12-10       Impact factor: 6.674

Review 3.  Tubulin-interactive natural products as anticancer agents.

Authors:  David G I Kingston
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

4.  Determination of 6258-70, a new semi-synthetic taxane, in rat plasma and tissues: Application to the pharmacokinetics and tissue distribution study.

Authors:  Simin Zhao; Yuanyuan Zhang; Ping Ju; Liqiang Gu; Rui Zhuang; Longshan Zhao; Xing Tang; Kaishun Bi; Xiaohui Chen
Journal:  J Pharm Anal       Date:  2016-03-02

Review 5.  Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer.

Authors:  Dmitriy Smolensky; Kusum Rathore; Maria Cekanova
Journal:  Drug Des Devel Ther       Date:  2016-10-05       Impact factor: 4.162
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.